Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Toddlers 12 to 23 Months of Age.

Trial Profile

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Toddlers 12 to 23 Months of Age.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 11 Jul 2017

At a glance

  • Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary)
  • Indications Meningococcal meningitis
  • Focus Pharmacodynamics
  • Sponsors sanofi pasteur
  • Most Recent Events

    • 28 Jun 2017 Planned primary completion date changed from 1 Dec 2017 to 15 Dec 2017.
    • 28 Jun 2017 Status changed from recruiting to active, no longer recruiting.
    • 19 Apr 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top